CRISPR Therapeutics AGCRSP

Market cap

$4.8B

P/E ratio

	2016/12	2017/12	2018/12	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12
Cash and cash equivalents	316	240	-	944	1,169	923	212	390	298
Marketable securities, current	-	-	-	-	522	1,456	1,603	1,304	1,606
Total cash & short-term investments	316	240	-	944	1,690	2,379	1,815	1,694	1,904
Accounts receivable, net	3	3	0	0	0	0	-	200	25
Total current assets	320	248	466	988	1,717	2,418	1,853	1,908	1,937
Property, plant and equipment, net	21	19	19	31	42	138	164	152	134
Marketable securities, non-current	-	-	-	-	-	-	53	2	-
Total non-current assets	25	23	23	79	111	334	390	321	305
Total assets	345	271	489	1,067	1,828	2,752	2,243	2,230	2,242
Accounts payable	5	2	5	6	9	15	27	38	15
Total current liabilities	22	15	28	57	94	120	121	109	88
Total non-current liabilities	90	69	69	70	69	233	246	238	222
Total liabilities	112	84	97	127	164	352	368	347	310
Common stock and paid-in capital	1	1	2	2	2	2	2	2	3
Retained earnings	-57	-125	-292	-225	-574	-196	-846	-1,000	-1,366
Stockholders' equity	233	188	392	939	1,664	2,399	1,875	1,883	1,932